Cargando…

LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs

WHAT IS KNOWN AND OBJECTIVE: Patients with kidney disease receiving immunosuppressive drugs (ISDs) (tacrolimus, cyclosporine and glucocorticoids) have a high risk of developing new‐onset diabetes mellitus (NODM). We aimed to establish a precise and convenient model for predicting NODM in patients re...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Lina, Luo, Chuxuan, Yuan, Chaoyun, Ye, Xiaolan, Zeng, Yuqun, Ren, Yan, Ye, Binxian, Li, Yiwen, Jin, Juan, He, Qiang, Shen, Xiaogang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796007/
https://www.ncbi.nlm.nih.gov/pubmed/35791031
http://dx.doi.org/10.1111/jcpt.13713
_version_ 1784860384552812544
author Shao, Lina
Luo, Chuxuan
Yuan, Chaoyun
Ye, Xiaolan
Zeng, Yuqun
Ren, Yan
Ye, Binxian
Li, Yiwen
Jin, Juan
He, Qiang
Shen, Xiaogang
author_facet Shao, Lina
Luo, Chuxuan
Yuan, Chaoyun
Ye, Xiaolan
Zeng, Yuqun
Ren, Yan
Ye, Binxian
Li, Yiwen
Jin, Juan
He, Qiang
Shen, Xiaogang
author_sort Shao, Lina
collection PubMed
description WHAT IS KNOWN AND OBJECTIVE: Patients with kidney disease receiving immunosuppressive drugs (ISDs) (tacrolimus, cyclosporine and glucocorticoids) have a high risk of developing new‐onset diabetes mellitus (NODM). We aimed to establish a precise and convenient model for predicting NODM in patients receiving immunosuppressive drugs. METHODS: This retrospective study recruited 1883 patients receiving ISDs between January 2010 and October 2018. The occurrence of NODM was the primary endpoint. The patients were randomly divided into training (n = 1318) and validation cohorts (n = 565) at a 7:3 ratio. A nomogram was established based on a least absolute shrinkage and selection operator (LASSO)‐derived logistic regression model. The nomogram's discrimination and calibration abilities were evaluated in both cohorts using the Hosmer‐Lemeshow test and calibration curves. Decision curve analysis (DCA) was used to evaluate the net benefit of the predictive efficacy. RESULTS AND DISCUSSION: Amongst the 1883 patients with kidney disease receiving immunosuppressive drugs, 375 (28.5%) and 169 (29.9%) developed NODM in the training (n = 1318) and validation cohorts (n = 565), respectively. Nine clinic predictors were included in this LASSO‐derived nomogram, which is easy to be operated clinically. The discriminative ability, determined by the area under the receiver operating characteristic curve (AUC), was 0.816 (95% confidence interval [CI] 0.790–0.841) and 0.831 (95%CI 0.796–0.867) in the training and validation cohorts, respectively. Calibration was confirmed with the Hosmer‐Lemeshow test in the training and validation cohorts (p = 0.238, p = 0.751, respectively). WHAT IS NEW AND CONCLUSION: Nearly one‐third of patients with kidney disease receiving immunosuppressive drugs developed NODM. The nomogram established in this study may aid in predicting the occurrence of NODM in patients with kidney disease receiving immunosuppressive drugs.
format Online
Article
Text
id pubmed-9796007
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97960072022-12-28 LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs Shao, Lina Luo, Chuxuan Yuan, Chaoyun Ye, Xiaolan Zeng, Yuqun Ren, Yan Ye, Binxian Li, Yiwen Jin, Juan He, Qiang Shen, Xiaogang J Clin Pharm Ther Original Articles WHAT IS KNOWN AND OBJECTIVE: Patients with kidney disease receiving immunosuppressive drugs (ISDs) (tacrolimus, cyclosporine and glucocorticoids) have a high risk of developing new‐onset diabetes mellitus (NODM). We aimed to establish a precise and convenient model for predicting NODM in patients receiving immunosuppressive drugs. METHODS: This retrospective study recruited 1883 patients receiving ISDs between January 2010 and October 2018. The occurrence of NODM was the primary endpoint. The patients were randomly divided into training (n = 1318) and validation cohorts (n = 565) at a 7:3 ratio. A nomogram was established based on a least absolute shrinkage and selection operator (LASSO)‐derived logistic regression model. The nomogram's discrimination and calibration abilities were evaluated in both cohorts using the Hosmer‐Lemeshow test and calibration curves. Decision curve analysis (DCA) was used to evaluate the net benefit of the predictive efficacy. RESULTS AND DISCUSSION: Amongst the 1883 patients with kidney disease receiving immunosuppressive drugs, 375 (28.5%) and 169 (29.9%) developed NODM in the training (n = 1318) and validation cohorts (n = 565), respectively. Nine clinic predictors were included in this LASSO‐derived nomogram, which is easy to be operated clinically. The discriminative ability, determined by the area under the receiver operating characteristic curve (AUC), was 0.816 (95% confidence interval [CI] 0.790–0.841) and 0.831 (95%CI 0.796–0.867) in the training and validation cohorts, respectively. Calibration was confirmed with the Hosmer‐Lemeshow test in the training and validation cohorts (p = 0.238, p = 0.751, respectively). WHAT IS NEW AND CONCLUSION: Nearly one‐third of patients with kidney disease receiving immunosuppressive drugs developed NODM. The nomogram established in this study may aid in predicting the occurrence of NODM in patients with kidney disease receiving immunosuppressive drugs. John Wiley and Sons Inc. 2022-07-05 2022-10 /pmc/articles/PMC9796007/ /pubmed/35791031 http://dx.doi.org/10.1111/jcpt.13713 Text en © 2022 The Authors. Journal of Clinical Pharmacy and Therapeutics published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Shao, Lina
Luo, Chuxuan
Yuan, Chaoyun
Ye, Xiaolan
Zeng, Yuqun
Ren, Yan
Ye, Binxian
Li, Yiwen
Jin, Juan
He, Qiang
Shen, Xiaogang
LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs
title LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs
title_full LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs
title_fullStr LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs
title_full_unstemmed LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs
title_short LASSO‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs
title_sort lasso‐derived nomogram predicting new‐onset diabetes mellitus in patients with kidney disease receiving immunosuppressive drugs
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796007/
https://www.ncbi.nlm.nih.gov/pubmed/35791031
http://dx.doi.org/10.1111/jcpt.13713
work_keys_str_mv AT shaolina lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT luochuxuan lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT yuanchaoyun lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT yexiaolan lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT zengyuqun lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT renyan lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT yebinxian lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT liyiwen lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT jinjuan lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT heqiang lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs
AT shenxiaogang lassoderivednomogrampredictingnewonsetdiabetesmellitusinpatientswithkidneydiseasereceivingimmunosuppressivedrugs